Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Monte Rosa Therapeutics Inc (GLUE)

189 + Investors. Track Smart Money conviction in GLUE. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +3
Streak
9Q ▲
Buyers last Q
56%

Smart Money Signals — GLUE

Based on 191 hedge funds · latest filing: 2026 Q2 · updated quarterly

📈

Buying streak — 9 quarters in a row

last 6Q
For 9 consecutive quarters, more hedge funds added GLUE than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
191 hedge funds hold GLUE right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +68% more funds vs a year ago

fund count last 6Q
+77 new funds entered over the past year (+68% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟡

Slight buying edge — 56% buying

110 buying88 selling
Last quarter: 110 funds bought or added vs 88 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
⚠️

Fewer new buyers each quarter (-19 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 25 → 50 → 51 → 32. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
📌

Mixed — 31% long-term, 42% new

■ 31% conviction (2yr+) ■ 27% medium ■ 42% new
Of the 191 current holders: 60 (31%) held >2 years, 51 held 1–2 years, and 80 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.
💰

Value +54% but shares only +7% — price-driven

Value
+53%
Shares
+6%
Last quarter: the total dollar value of institutional holdings rose +54%, but actual share count only changed +7%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
📈

Growing discovery — still being found

25 → 25 → 50 → 51 → 32 new funds/Q
New funds entering each quarter: 25 → 50 → 51 → 32. A growing number of institutions are discovering GLUE each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.
📊

Mixed cohorts — 38% veterans, 47% new entrants

■ 38% veterans ■ 15% 1-2yr ■ 47% new
Of 197 current holders: 75 (38%) held 2+ years, 30 held 1–2 years, 92 (47%) entered in the past year. Balanced distribution — some institutional memory, some recent momentum buyers.
✅

Strong quality — 30% AUM from major funds

30% from top-100 AUM funds
45 of 189 holders rank in the top 100 by AUM, accounting for 30% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
4.9
out of 10
Moderate Exit Risk
Exit risk score 4.9/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — GLUE

In 2026 Q2, 110 hedge funds were net buyers of GLUE (32 opened a new position, 78 added to an existing one), while 88 reduced or exited (59 trimmed, 29 sold completely) — a 56% buyer ratio, indicating a slight buying edge. This marks 9 consecutive quarters of net institutional buying — a persistent conviction signal. 30% of total institutional value in GLUE is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: +3 funds (more new holders than closures). Total institutional holders: 191.

Hedge Fund Ownership: GLUE

How many hedge funds hold GLUE — quarterly history vs. share price
Quarterly hedge fund ownership of GLUE vs. share price

Market Analysis: GLUE

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: GLUE

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Loading signal freshness…
Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

11 top-rated funds 7 high-conviction
Consensus
4.7
/ 10
breadth
×
Elite
3.8
/ 10
conviction
Hedge Fund Positioning: GLUE
189 + Investors

Track Smart Money conviction in GLUE. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q2) Prior (2026 Q1) Change
Funds Holding 189 188 0.53%
13F Shares 93M 87M 6.91%
Total Value $2.02B $1.31B 53.72%
New Positions 32 51 -19
Increased Positions 77 82 -5
Closed Positions 29 21 +8
Reduced Positions 58 41 +17
Total Calls 6 3 100.0%
Total Puts 2 3 -33.33%
PUT/CALL Ratio 0.33 1.0 Bullish

Statistics: GLUE

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

189 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in GLUE. Verified SEC 13F-HR filings.

QUARTER:
Top 25 GLUE holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Versant Venture Management, LLC 47.34% 3,180,780 $77.0M
2 NEA Management Company, LLC 11.72% 7,692,298 $186.2M
3 Aisling Capital Management LP 7.98% 1,555,664 $37.6M
4 Boone Capital Management LLC 3.48% 615,287 $14.9M
5 Silverarc Capital Management, LLC 2.79% 1,108,295 $26.8M
6 Bvf Inc/Il 2.76% 4,460,886 $108.0M
7 TCG Crossover Management, LLC 2.69% 4,622,151 $111.9M
8 Vestal Point Capital, LP 2.60% 4,600,000 $111.3M
9 Braidwell LP 2.19% 2,451,562 $59.3M
10 Exome Asset Management LLC 2.05% 137,115 $3.3M
11 MPM BioImpact LLC 1.71% 1,161,081 $28.1M
12 Opaleye Management Inc. 1.63% 745,000 $18.0M
13 Montanova Capital, LLC 1.57% 3,549,539 $85.9M
14 Nextech Invest Ltd. 0.87% 761,153 $18.4M
15 Stempoint Capital LP 0.64% 153,544 $3.7M
16 Bellevue Group AG 0.61% 1,190,000 $28.8M
17 Act Capital Management, LLC 0.55% 35,000 $847K
18 Baker BROS. Advisors LP 0.53% 4,345,736 $105.2M
19 Frazier Life Sciences Management, L.P. 0.53% 1,000,000 $24.2M
20 Nantahala Capital Management, LLC 0.53% 651,993 $15.8M
21 Diadema Partners LP 0.52% 170,100 $4.1M
22 PSP Research LLC 0.30% 23,000 $557K
23 AlphaCentric Advisors LLC 0.26% 12,645 $306K
24 Persistent Asset Partners Ltd 0.25% 34,083 $825K
25 ADAR1 Capital Management, LLC 0.24% 216,752 $5.2M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Monte Rosa Therapeutics Inc (GLUE)

What does the Smart Money Trend signal show for GLUE?

Buying streak — 9 quarters in a row: For 9 consecutive quarters, more hedge funds added GLUE than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for GLUE?

Slight buying edge — 56% buying: Last quarter: 110 funds bought or added vs 88 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for GLUE holders?

Strong quality — 30% AUM from major funds: 45 of 189 holders rank in the top 100 by AUM, accounting for 30% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held GLUE?

Mixed — 31% long-term, 42% new: Of the 191 current holders: 60 (31%) held >2 years, 51 held 1–2 years, and 80 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →